Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
Cancer Invest
; 30(1): 1-12, 2012 Jan.
Article
en En
| MEDLINE
| ID: mdl-22236184
The development of new therapies for castration-resistant prostate cancer (CRPC) has increasingly focused on improving patient quality of life, mainly because of limited survival gains and continuing high morbidity burden from disease progression or the adverse effects of treatments. However, there is no generally accepted quality of life instrument for use with this patient group. This paper objectively reviews the existing literature and assesses the impact of CRPC treatments on patients' quality of life. The review also provides a narrative description of the evolving role of quality of life measures in clinical trials, and critiques the most widely used instruments.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Calidad de Vida
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Antagonistas de Andrógenos
Tipo de estudio:
Risk_factors_studies
Aspecto:
Patient_preference
Límite:
Humans
/
Male
Idioma:
En
Revista:
Cancer Invest
Año:
2012
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Reino Unido